Egetis Therapeutics AB (publ)
STO:EGTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.1
9.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ)
Total Equity
Egetis Therapeutics AB (publ)
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Egetis Therapeutics AB (publ)
STO:EGTX
|
Total Equity
kr545.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Equity
kr2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Equity
kr661.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Equity
kr13.1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
50%
|
CAGR 10-Years
42%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Equity
kr37.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
23%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Equity
kr1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Egetis Therapeutics AB (publ)
Glance View
Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
See Also
What is Egetis Therapeutics AB (publ)'s Total Equity?
Total Equity
545.6m
SEK
Based on the financial report for Dec 31, 2023, Egetis Therapeutics AB (publ)'s Total Equity amounts to 545.6m SEK.
What is Egetis Therapeutics AB (publ)'s Total Equity growth rate?
Total Equity CAGR 5Y
20%
Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Egetis Therapeutics AB (publ) have been -5% over the past three years , 20% over the past five years .
You don't have any saved screeners yet